Atezolizumab Plus Bevacizumab Does Not Improve OS in Renal Cell Carcinoma
The overall survival results were similar between the treatment arms for the overall cohort and for patients with PD-L1+ disease.
Renal Cell Carcinoma News
RENAL CELL CARCINOMA ADVISOR
Renal Cell Carcinoma News
HLA Variant May Predict Poor Outcomes of Immunotherapy in Cancer Patients
HLA-A*03 was associated with worse progression-free and overall survival.
Tumor Size Affects Survival After Cytoreductive Nephrectomy for RCC
There is no universal approach to patient selection for cytoreductive nephrectomy.
Diabetes Not a Major Driver of Oncologic Outcomes in Renal Cell Carcinoma
Researchers have questioned whether diabetes exerts adverse effects on the prognosis of RCC.
Belzutifan Demonstrates Efficacy in VHL-Associated Renal Cell Carcinoma
Belzutifan demonstrated activity against both RCC and non-RCC neoplasms associated with VHL disease.
Can Quality of Life Assessments Predict PFS, OS Across Cancer Types?
Recent studies showed associations between quality of life scores and survival in lung and prostate cancer as well as renal cell carcinoma.
Radiation Therapy for Oligometastatic Renal Cell Carcinoma Promising
Serial radiation therapy could provide an alternative to standard-of-care systemic therapy.
Adverse Radiologic and Pathologic Features Predict Worse Survival Outcomes in Small Renal Masses Following Nephrectomy
Researchers hypothesized that adverse radiologic and pathologic T3 features are predictive of worse outcomes in small renal masses.
Cytoreductive Nephrectomy Plus Active Surveillance Benefits Some With Metastatic Renal Cell Carcinoma
The median cancer-specific survival was 56.5 months.
First-Line Nivolumab Plus Ipilimumab May Offer Greater Cost Efficiency Than Pembrolizumab Plus Axitinib in Advanced Renal Cell Carcinoma
The monthly incremental cost per survivor relative to sunitinib for nivolumab plus ipilimumab decreased over time from $90,035 for 12 months to $18,881 for 48 months.
Predicting Long-Term Survival With Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma
Patients with smaller target lesions at baseline were more likely to be long-term survivors.
Oncologists Appear to Prefer IO/IO to IO/TKI Combinations in First-Line Metastatic Renal Cell Carcinoma
The investigators aimed to understand how oncologists decide between IO/IO and IO/TKI treatment options via survey.
Gene Expression Profiling Could Inform Treatment of Non-Clear Cell Renal Cell Carcinoma
Nearly half of non-clear cell renal cell carcinoma samples were classified as proliferative.
Managing Adverse Reactions to Lenvatinib-Pembrolizumab
The median time to first onset of key adverse reactions was within 5 months of starting lenvatinib-pembrolizumab.
5-year Follow-Up: First-Line Nivolumab Plus Ipilimumab vs Sunitinib in Advanced Renal Cell Carcinoma
Investigators presented the longest phase 3 follow-up reported for a checkpoint inhibitor combination therapy in aRCC.
Real-World Characteristics and Treatment Patterns in Advanced Renal Cell Carcinoma Treated With First-Line Avelumab Plus Axitinib
Researchers determined that few patients with poor risk aRCC were receiving first-line avelumab plus axitinib.
BRCA1-Associated Protein 1 Suppresses Tumor Growth via Interferon-β in Clear Cell Renal Cell Carcinoma
Patients with BAP1-mutant ccRCC have very poor prognosis and comprise 10% to 15% of ccRCC cases.
COVID-19 Vaccines Deemed Safe for Renal Cell Carcinoma Patients on Immune Checkpoint Inhibitors
The rate of new or worsening immune-related adverse events was no higher than previously reported.
Radiation Prior to Immunotherapy May Not Affect Outcomes in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases
No major difference in outcome was observed in a retrospective analysis of patients with mRCC and bone metastasis treated with IO with and without prior radiation.
Disease-Free Survival Predicts Overall Survival in Localized Renal Cell Carcinoma After First Nephrectomy
Investigators assessed the association between DFS and OS in patients with newly diagnosed, completely resected, intermediate-high or high-risk RCC post-nephrectomy.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...